BANK VONTOBEL/CALL/NOVO NORDISK ADR B/210/0.1/17.01.25 | Real-time Boerse Frankfurt Warrants 02:04:01 2024-07-16 pm EDT | ||
| 0.108 EUR | -4.42% |
|
| Current month | -31.21% | ||
| 1 month | -31.21% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-07-16 | 0.108 | -4.42% |
| 24-07-15 | 0.113 | -8.13% |
| 24-07-12 | 0.123 | +24.24% |
| 24-07-11 | 0.099 | -23.85% |
| 24-07-10 | 0.13 | +8.33% |
Real-time Boerse Frankfurt Warrants
Last update July 16, 2024 at 02:04 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| WKN | VD10NR |
| ISIN | DE000VD10NR1 |
| Date issued | 2024-03-12 |
| Strike | 210 $ |
| Maturity | 2025-01-17 (185 Days) |
| Parity | 10 : 1 |
| Emission price | 0.25 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.39 € |
|---|---|
| Lowest since issue | 0.076 € |
| Spread | 0.01 € |
| Spread % | 10.53% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
970
DKK
Average target price
956.8
DKK
Spread / Average Target
-1.36%
- Stock Market
- Warrants
- Warrant
